- Home
- LXFR vs YMAB Comparison
LXFR vs YMAB Comparison
Compare LXFR & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXFR
- YMAB
- Stock Information
- Founded
- LXFR 1898
- YMAB 2015
- Country
- LXFR United States
- YMAB United States
- Employees
- LXFR N/A
- YMAB N/A
- Industry
- LXFR Major Chemicals
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- LXFR Industrials
- YMAB Health Care
- Exchange
- LXFR Nasdaq
- YMAB Nasdaq
- Market Cap
- LXFR 331.9M
- YMAB 386.7M
- IPO Year
- LXFR 2012
- YMAB 2018
- Fundamental
- Price
- LXFR $12.45
- YMAB $8.52
- Analyst Decision
- LXFR
- YMAB Buy
- Analyst Count
- LXFR 0
- YMAB 11
- Target Price
- LXFR N/A
- YMAB $15.02
- AVG Volume (30 Days)
- LXFR 129.1K
- YMAB 1.9M
- Earning Date
- LXFR 07-29-2025
- YMAB 08-08-2025
- Dividend Yield
- LXFR 4.15%
- YMAB N/A
- EPS Growth
- LXFR N/A
- YMAB N/A
- EPS
- LXFR 0.90
- YMAB N/A
- Revenue
- LXFR $403,800,000.00
- YMAB $85,385,000.00
- Revenue This Year
- LXFR $2.63
- YMAB N/A
- Revenue Next Year
- LXFR $3.30
- YMAB $15.23
- P/E Ratio
- LXFR $12.83
- YMAB N/A
- Revenue Growth
- LXFR 5.60
- YMAB N/A
- 52 Week Low
- LXFR $9.41
- YMAB $3.55
- 52 Week High
- LXFR $15.64
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- LXFR 54.41
- YMAB 81.55
- Support Level
- LXFR $12.36
- YMAB $8.50
- Resistance Level
- LXFR $12.68
- YMAB $8.54
- Average True Range (ATR)
- LXFR 0.38
- YMAB 0.07
- MACD
- LXFR 0.04
- YMAB 0.08
- Stochastic Oscillator
- LXFR 70.00
- YMAB 99.54
About LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.